Posted On: 02/23/2014 9:22:47 PM
Post# of 36729
Re: Agent 0001 #25147
GoldNApel's Berkeley Bio is exclusive to SKTO, a 100% owned subsidiary of SK.
A key word here is "exclusive."
"On June 30, 2013, SK3 Group closed an acquisition agreement to acquire 100% of the assets of BBORL, INC (Berkeley Bio-Organic Research Laboratories), a California Corporation for 20 million shares of SK3 Group, common stock, valued at the closing market price of $0.0182 on the closing date, or a total of $364,000.
The main concentration of BBORL is consultation with many collectives in the development and production of non-psychoactive cannabinoid medicines, primarily for the treatment of cancer, allowing patients to obtain medically efficacious doses without attendant, and possibly negative, psychoactive consequences.
A secondary interest is the development and production of equipment for the manufacture and production of cannabinoid-based medicines. Berkeley Bio has made substantial strides in these areas.
The principal assets acquired consisted of the intellectual property and knowhow developed by BBORL, Inc. through its former operations. BBORL, Inc. remains an independent company but provides research and development services to the Company in the medical marijuana field on an exclusive basis."
A key word here is "exclusive."
"On June 30, 2013, SK3 Group closed an acquisition agreement to acquire 100% of the assets of BBORL, INC (Berkeley Bio-Organic Research Laboratories), a California Corporation for 20 million shares of SK3 Group, common stock, valued at the closing market price of $0.0182 on the closing date, or a total of $364,000.
The main concentration of BBORL is consultation with many collectives in the development and production of non-psychoactive cannabinoid medicines, primarily for the treatment of cancer, allowing patients to obtain medically efficacious doses without attendant, and possibly negative, psychoactive consequences.
A secondary interest is the development and production of equipment for the manufacture and production of cannabinoid-based medicines. Berkeley Bio has made substantial strides in these areas.
The principal assets acquired consisted of the intellectual property and knowhow developed by BBORL, Inc. through its former operations. BBORL, Inc. remains an independent company but provides research and development services to the Company in the medical marijuana field on an exclusive basis."
(0)
(0)
